A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events
Abstract
Background: Effects of ω-3 fatty acids (FAs) supplementation on cardiovascular outcomes have been investigated in several randomized controlled trials (RCTs). The VITamin D and OmegA-3 TriaL (VITAL) is the largest trial that tested the effect of ω-3 FA supplementation (840 mg/d of eicosapentaenoic acid and docosahexaenoic acid in 1.2:1) in a primary prevention population in the United States, with nonsignificant results (P > 0.05) for major cardiovascular disease (CVD) events.
Objectives: To reanalyze VITAL using Bayesian methods accounting for prior evidence.
Methods: The VITAL randomly assigned 25,871 older United States adults with a median follow-up of 5.3 y. On the basis of prior evidence from RCTs, we used Weibull proportional hazards models adopting the Hamiltonian Monte Carlo sampling method to estimate posterior hazard ratio (HR) for total CAD, myocardial infarction (MI), composite major CVD events (CAD/stroke/CVD death), CVD death, all-cause death, and stroke. Several distinct informative priors were formulated based on Bayesian hierarchical models of previous trials similar to VITAL.
Results: Bayesian analyses with the use of noninformative prior yielded essentially the same results as the corresponding frequentist analyses. The effects of ω-3 FA supplementation on CAD and MI were robust across the priors, with the posterior HR estimates varying from 0.88 to 0.93 and 0.82 to 0.90, respectively. Without skepticism into the priors, posterior HRs were 0.95-0.96 in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.